Key Points
- CEO sold 5,156 shares: Athira Pharma CEO Mark James Litton sold 5,156 shares on March 4 at an average price of $5.37 for about $27,688, reducing his ownership by 8.17% to 57,926 shares, as disclosed in an SEC Form 4.
- Stock context: shares traded around $5.45 (up $0.08) with a market cap of $21.49 million, a 12‑month range of $2.20–$8.36, and a negative P/E, reflecting a small, volatile clinical‑stage biopharma profile.
- Mixed analyst views: recent reports range from "sell" to "overweight," with Mizuho upgrading to "outperform," and MarketBeat shows a consensus of "Hold" with a $10 target price.
Athira Pharma, Inc. (NASDAQ:LONA - Get Free Report) CEO Mark James Litton sold 5,156 shares of the company's stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $5.37, for a total transaction of $27,687.72. Following the completion of the transaction, the chief executive officer owned 57,926 shares in the company, valued at approximately $311,062.62. This represents a 8.17% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Athira Pharma Stock Performance
Shares of NASDAQ LONA traded up $0.08 during mid-day trading on Friday, reaching $5.45. 9,148 shares of the company were exchanged, compared to its average volume of 65,726. The stock has a market cap of $21.49 million, a PE ratio of -0.56 and a beta of 2.68. Athira Pharma, Inc. has a twelve month low of $2.20 and a twelve month high of $8.36.
Analyst Ratings Changes
LONA has been the topic of several research reports. Zacks Research raised Athira Pharma to a "hold" rating in a research report on Friday, February 27th. Weiss Ratings initiated coverage on Athira Pharma in a research report on Wednesday, February 11th. They set a "sell (d-)" rating on the stock. Cantor Fitzgerald assumed coverage on shares of Athira Pharma in a research report on Thursday, February 26th. They issued an "overweight" rating for the company. Wall Street Zen lowered shares of Athira Pharma from a "hold" rating to a "sell" rating in a research report on Saturday, February 28th. Finally, Mizuho upgraded shares of Athira Pharma from a "neutral" rating to an "outperform" rating and set a $10.00 price objective for the company in a research note on Thursday, February 19th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $10.00.
Check Out Our Latest Stock Analysis on Athira Pharma
About Athira Pharma
(
Get Free Report)
Athira Pharma, traded as LONA on the NASDAQ, is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule therapeutics intended to restore neuronal health and function in neurodegenerative and cognitive disorders. The company's research approach centers on modulating pathways involved in synaptic repair and neurotrophic signaling to address underlying neuronal dysfunction rather than solely treating symptoms.
Athira's lead investigational therapy is fosgonimeton (ATH-1017), a small-molecule candidate designed to potentiate hepatocyte growth factor (HGF)/MET pathway signaling with the aim of improving synaptic connectivity and cognitive performance in patients with conditions such as Alzheimer's disease and related cognitive impairments.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
